RECRUITING

Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial

Description

This clinical trial evaluates remotely delivered, community-aligned weight loss interventions in Latina breast cancer survivors. Breast cancer is the second leading cause of cancer death among women in the US. There are population differences in breast cancer mortality, based on specific risk factors, including obesity. Cancer is the leading cause of death among Latinos, and among Latinas, breast cancer is the leading cause of cancer death. An estimated 80% of Latinas in the United States have overweight/obesity, which is associated with poorer breast cancer outcomes. However, few, if any, effective interventions exist to promote and maintain weight loss in Latina breast cancer survivors. The development of an adaptive program that provides survivors with the support they need, as opposed to what is typically available, to improve breast cancer survivorship.

Conditions

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8
Talk to us

Related Conditions:

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8

Study Overview

On this page

Study Details

Study overview

This clinical trial evaluates remotely delivered, community-aligned weight loss interventions in Latina breast cancer survivors. Breast cancer is the second leading cause of cancer death among women in the US. There are population differences in breast cancer mortality, based on specific risk factors, including obesity. Cancer is the leading cause of death among Latinos, and among Latinas, breast cancer is the leading cause of cancer death. An estimated 80% of Latinas in the United States have overweight/obesity, which is associated with poorer breast cancer outcomes. However, few, if any, effective interventions exist to promote and maintain weight loss in Latina breast cancer survivors. The development of an adaptive program that provides survivors with the support they need, as opposed to what is typically available, to improve breast cancer survivorship.

Using a SMART Design to Evaluate Remotely Delivered, Community-aligned Weight Loss Interventions Among Breast Cancer Survivors

Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial

Condition
Anatomic Stage I Breast Cancer AJCC v8
Intervention / Treatment

-

Contacts and Locations

Seattle

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Biologically female
  • * Age \>= 18 years
  • * Self-identifies Hispanic/Latina
  • * Fluent in Spanish and/or English
  • * Previously diagnosis of stage I-III BC within the past 5 years
  • * No evidence of current, recurrent, or metastatic disease
  • * \> 60 days post treatment (current endocrine therapy allowed)
  • * Body mass index (BMI) \>= 27 kg/m\^2 initially assessed via self-reported height and weight and confirmed prior to randomization via a tape measure and Bluetooth-enabled scale
  • * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • * Willingness to participate in all study activities
  • * Access to phone for study contacts
  • * Access to internet and smartphone, tablet, or computer to participate in the online program and to be able to sync study WiFi devices
  • * Access to internet to participate in the online program and to be able to sync study devices
  • * Successful completion of at-home baseline assessments prior to randomization
  • * Body mass index (BMI) \< 27 kg/m\^2
  • * Diabetic with current use of insulin or sulfonylurea medications (note: current use of metformin is allowed)
  • * Major comorbidities or physical limitations that would preclude from healthy weight loss, reducing energy intake or engaging in PA
  • * Pregnant, breastfeeding, or planning to become pregnant during the study period
  • * Use of exogenous hormones for gender affirmation

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Fred Hutchinson Cancer Center,

Heather Greenlee, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

2028-03-01